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Identification of clinical target areas in the brainstem of prion-infected mice
Aims:While prion infection ultimately involves the entire
brain, it has long been thought that the abrupt clinical
onset and rapid neurological decline in laboratory rodents
relates to involvement of specific critical neuroanatomical
target areas. The severity and type of clinical signs,
together with the rapid progression, suggest the brainstem
as a candidate location for such critical areas. In this study
we aimed to correlate prion pathology with clinical phe-
notype in order to identify clinical target areas. Method:
We conducted a comprehensive survey of brainstem
pathology in mice infected with two distinct prion strains,
which produce different patterns of pathology, in mice
overexpressing prion protein (with accelerated clinical
onset) and in mice in which neuronal expression was
reduced by gene targeting (which greatly delays clinical
onset). Results:We identified specific brainstem areas that
are affected by prion pathology during the progression of
the disease. In the early phase of disease the locus
coeruleus, the nucleus of the solitary tract, and the pre-
Bötzinger complex were affected by prion protein deposi-
tion. This was followed by involvement of the motor and
autonomic centres of the brainstem. Conclusions:
Neurodegeneration in the locus coeruleus, the nucleus of
the solitary tract and the pre-Bötzinger complex predomi-
nated and corresponded to the manifestation of the clini-
cal phenotype. Because of their fundamental role in
controlling autonomic function and the overlapwith clini-
cal signs in sporadic Creutzfeldt–Jakob disease, we suggest
that these nuclei represent key clinical target areas in
prion diseases.
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Introduction
The most frequent form of human prion disease, sporadic
Creutzfeldt–Jakob disease (sCJD) typically presents as
a rapidly progressive multifocal dementia. Typically,
patients progress to akinetic mutism and death within 4
months. Frequent neurological features include myo-
clonus, extrapyramidal signs, cerebellar ataxia, pyramidal
signs and cortical blindness. Some of the clinical signs
suggest brainstem involvement, for example dysphagia,
dysarthria, respiratory failure and ophthalmoplegia.
Histologically, affected areas show evidence of neuro-
degeneration with vacuolation (spongiosis) [1–3], the
pathogenesis of which is still debated. It may arise from
abnormal membrane permeability and increased water
content in the neurones [4], from autophagy [5], or may
be due to production of abnormal prion protein (PrP)
within the lysosomal compartment, which would cause
disruption of the lysosomal membrane, destruction of the
neuronal cytoskeleton and initiation of vacuolation [6].
Other histological features are loss of neurones, invariably
accompanied by astrocytic proliferation (gliosis) and
microglial activation. Usually these findings correlatewith
the deposition of abnormal (disease-associated) prion
protein. According to the protein-only hypothesis [7,8],
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prions consist of multichain forms of misfolded host-
encoded cellular prion protein (PrPC), referred to as PrPSc,
and propagate by an autocatalytic process of seeded
fibrillization [9,10]. It is still unclear how prion propaga-
tion results in neurodegeneration and clinical onset. Prion
propagation and neurotoxicity can be uncoupled in
animalmodels; prions themselvesmay not be directly neu-
rotoxic [11,12], and neurotoxicity may relate to produc-
tion of toxic species distinct from the propagating
infectious species but catalysed by them [9]. Infectionwith
a defined prion strain in a distinct inbred mouse line is
associated with prolonged but remarkably consistent
incubation periods followed by a very rapid clinical phase.
Recent work measuring the kinetics of prion propagation
in mice with different levels of PrPC expression described
two distinctmechanistic phases during the clinically silent
incubation period.
In the first phase, prions propagate exponentially, not
rate-limited by PrPC concentration, until a defined
maximal titre is reached, arguing that infectious prions
comprise a small minority of available PrP. In the second
plateau phase, there is a linear rise in Proteinase K (PK)
sensitive disease-related PrP isoforms, a mechanistically
distinct process rate limited by, and directly proportional
to, PrPC concentration. Clinical onset occurs at a similar
level of PK-sensitive disease-related PrP isoforms, irre-
spective of PrPC expression level. Prion titres are essen-
tially constant, and the length of this plateau to clinical
onset is inversely proportional to PrPC expression level
[13,14]. It is argued that a toxic species PrP lethal (PrPL)
[12,15] is formed in this second phase by a process linearly
related to PrPC concentration, and neurodegenerative
changes occur when PrPL reaches a local toxic threshold.
The histopathological correlate of the preclinical phase is
a mild accumulation of abnormal PrP, activation and pro-
liferation of astrocytes [16–18] and microglia cells
[19,20]. The progression to the clinical phase is charac-
terized by additional synaptic loss and increasing
spongiform degeneration, followed by neuronal death
[21].
However, it is still not clear how the distribution of prion
disease-related pathology in different brain regions relates
to the onset and progression of disease. Earlier studies
focused on the effect of different routes of infection on the
clinical phase of prion disease. It was reported that the
scrapie replication phase in the brain was shorter after
peripheral administration of prions (intraperitoneal, or
i.p.), than after direct intracerebral inoculation (i.c.) in the
forebrain [22–24]. This observation led to the postulation
that the development of clinical prion disease depends on
prion infection spreading to specific ‘clinical target areas’
resulting in cell dysfunction and cell death. It was there-
fore speculated that the duration of the ‘neural’ phase of
pathogenesis is determined by the complexity of the path-
ways between the entry site of infection (injection site)
and the postulated clinical target areas in which scrapie
should replicate for the disease to develop [22]. Clinical
signs highly suggestive of brainstem involvement are seen
in experimental rodent models of prion disease: brainstem
nuclei control essential body functions such as motor
control, generation of the respiratory rhythm and regula-
tion of the blood pressure, and indeed, unsteady gait is an
early clinical manifestation and abnormal respiration is a
key late feature.
In humans, widespread PrP deposition in the brainstem
has been reported as an early pathologic event in
sCJD [25]. This study correlated clinical signs and
histopathological changes in 33 sCJD brainstems. It
showed high variability among samples andwas unable to
determine a correlation between clinical signs and
brainstem lesions. However, brainstem atrophy, neuronal
loss, pyramidal tract degeneration and PrP deposition
were reported, particularly in patients with prolonged
disease. The authors speculated that a conclusive evalua-
tion on the relation between clinical signs and brainstem
impairment is difficult because the same symptoms could
derive from overlapping involvement of basal ganglia or
cortex [25].
Mouse models have the advantage of avoiding the
variability of human pathology and to directly correlate
the temporal relationship between onset of clinical signs
and brainstem involvement. In previous studies, mice in
which neuronal PrPC expression was ablated during
established CNS infection with the Rocky Mountain
Laboratories (RML) prion strain were significantly pro-
tected against onset of clinical disease [26]. We repeated
these studies using both RML and ME7 prion strains in
single transgenic mice with overexpression of PrPC
(MloxP line) and double transgenic mice in which the
PrP transgene can be deleted by Cre-mediated excision
(NFH-Cre/MloxP line), to see if we could relate onset of
brainstem pathology to clinical onset in these models
with different pathogenesis and incubation periods. Pre-
vious studies have shown that the first manifestation of
prion pathology occurs in the thalamus and brainstem in
PrPC overexpressing RML prion-inoculated [27] and ME7
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prion-inoculated mice (Figure S3). Double transgenic
mice are particularly useful for this study as they have a
mild and significantly protracted disease progression,
which will allows us to study the localized accumulation
of abnormal PrP and the developing pathological
changes at a higher temporal resolution [26,28,29].
Also, we aimed at a comparison with previously charac-
terized models and their kinetics [26].
Here,we setout to systematically investigate theputative
clinical target areas of prion disease by a comprehensive
analysis of the evolution of brainstem pathology in these
models [27]. We observed early colonization of specific
nuclei in the brainstem and followed the disease progres-
sion in these areas. Although the thalamus showed early
signs of prion protein deposition, we specifically investi-
gated the brainstem, where the nuclei play a role in con-
trolling autonomic functions and survival. We propose
that loss of neuronal tissue within the brainstem nuclei
may explain some of the clinical symptoms in terminal
prion disease and suggest that they may represent specific
clinical target areas for prion disease. The critical role of
thesenuclei inmaintenanceof essentialneurological func-
tion may explain the rapidity of clinical decline in some
animal models and human prion diseases.
Materials and methods
Experimental animals
All animal experiments conformed to United Kingdom
regulations and institutional guidelines and were per-
formed under Home Office project license (PPL70/6454).
MloxP and NFH-Cre/MloxP transgenic mice were gen-
erated as described in detail previously [26,29] on a
Prnp0/0 background where PrP is expressed under the
control of a hemizygous PrP (MloxP) transgene, on an
inbred FVB/N background. These mice show a decreas-
ing expression of PrPC at 8–10 weeks due to a late onset
NFH-cre mediated removal of PrP expression. ROSA26
reporter mice for cre activity (ROSA26Lox) were used to
detect Cre-mediated recombination [30]. ROSA26Lox
homozygous mice were crossed to homozygous NFH-Cre
mice, to obtain hemizygous mice for both transgenes
(LacZ and NFH-Cre) to be used for β-galactosidase
immunohistochemistry.
NFH-Cre/MloxP mice result from the cross of MloxP
mice and NFH-Cre mice, expressing Cre recombinase
under control of Neurofilament Heavy Chain promoter
[31], which targets expression to adult neurones [29]. In
double transgenic mice, the Cre enzyme excises the PrP
coding sequences placed within the two loxP sites, effec-
tively eliminating PrP expression in the recombined cells
[29]. Thus, double transgenic NFH-Cre/MloxP mice
expressPrP inneuronesandnon-neuronal cellsuntil 8–12
weeksof age,whentheyundergoCre-mediateddepletionof
neuronal PrPC. Also the efficacy of recombination varies
between brain regions, explaining the sustained produc-
tion of PrPSC while survival is significantly prolonged [26].
These transgenic animals were chosen over wild type
strains as they allow for a detailed, anatomically selective
functional and anatomical-pathological analysis and cor-
relation.Micewere individually taggedwith subcutaneous
transponders for unequivocal identification and housed in
a temperature- and light-controlled mouse room (12 h
light/dark cycles) ingroupsof four to sixmice.Allmicehad
free access to food and water.
Mice were examined daily for early signs of prion
disease and culled when defined diagnostic clinical signs
occurred, or time-culled at 6 and 12 (RML infection) or 8
and 16 (ME7 infection) weeks post-inoculation (wpi). All
brains were collected and processed for histology, of which
three or more mice per group were analysed in detail his-
tologically. Cohorts of at least 10 mice of the genotypes
MloxP and NFH-Cre/MloxP were inoculated with RML or
ME7 and were observed until scrapie end stage to deter-
mine survival curves or were time culled. Mice dying
within 4 weeks of the inoculation were excluded from the
analysis.
Neurological observation
Following inoculation with RML or ME7 prions, mice
were examined daily for appearance of scrapie symptoms
or other signs of illness. Early indicators of prion disease
include erect ears, rigid tail, piloerection and ungroomed
appearance; slightly hunched posture; and clasping of
hind limbs when lifted; confirmatory signs include
ataxia, generalized tremor, impaired breathing activity,
loss of righting reflex or limb paralysis. The clinical signs
that defined an experimental mouse as terminally ill are
suggestive of brainstem malfunction affecting both
motor control (unsteady gate, tremor and ataxia) and
respiratory control (abnormal breathing rate). For end-
point experiments, animals were culled as soon as clini-
cal prion disease was confirmed or if they showed signs
of distress or loss of 20% of body weight. All symptoms
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were recorded on videotape prior to culling of the
animal.
Preparation of prion inocula and inoculation
of animals
Hemizygous MloxP and NFH-Cre/MloxP mice were inocu-
lated with Rocky Mountain Laboratories (RML) or ME7
prion strains. RML (MRC Prion Unit Inoculum reference
I8700) andME7 (I9458) prion inocula were prepared as a
10% (w/v) brain homogenate in Dulbecco’s phosphate
buffered saline lacking Ca2+ orMg2+ ions (D-PBS) and titred
by bioassay inTg20mice (19). Prion titres were calculated
using the Reed–Muench formula (I8700 titre = 8.2 Log
LD50/g brain; I9458 titre = 9 Log LD50/g brain). I8700
and I9458were diluted to 1% (w/v) with D-PBS and 20 μl
of 1% brain homogenate were inoculated intracerebrally
into the right parietal lobe of anesthetized 1-week-old
mice. The inoculation at this early time point was neces-
sary to allow for development of prion disease before the
onset of recombination and loss of PrP expression in the
CNS as described previously [26,28,29]. Following intrac-
erebral inoculation, prions are distributed widely in the
CNS rather than in a specific location [24,27,32], but
eventually pathological changes appear in specific areas.
In the mouse strains used here, the first two areas of prion
replication and detection of abnormal prion protein, inde-
pendent of the precise inoculation site, are the thalamus
and the dorsal brainstem.
Histology
Brains from time-culled or terminally ill mice were fixed
in 10 % buffered formal saline. Brains were dissected on
the level of the striatum, the anterior hippocampus/
thalamus and the midbrain with the rostral end of the
cerebellum. Each of the slices was processed separately
and embedded in paraffin wax. Serial coronal sections
from the most caudal block, corresponding to the
brainstem and the cerebellum, were cut at a nominal
thickness of 3 μm, with five consecutive serial sections,
followed by a 50 μm gap between levels, to allow a repro-
ducible and consistent analysis of all brainstem regions.
Brain sections were stained with haematoxylin-eosin and
prepared for immunohistochemical staining. Antibodies
or antisera against the following antigens were used:
PrP (ICSM35, D-Gen London UK), glial fibrillary acidic
protein (GFAP) (DAKO Z0334 Ely, UK), β-galactosidase
(Abcam Ab616 Cambridge, UK), ionized calcium-binding
adapter molecule 1 (Iba-1) (Abcam 5076) and
Neurokinin 1 (NK1) receptor (Pierce PA1-32229 Hemel
Hempstead, UK). All immunostainings were carried
out on the automated Ventana Benchmark XT or Discov-
ery XT (Roche Burgess Hill, UK) staining instrument,
using biotinylated secondary antibodies and a horserad-
ish peroxidase-conjugated streptavidin complex and
diaminobenzidine as a chromogen.
Semi-quantitative neuropathological analysis
and region mapping
Sections of brains from time-culled mice and from those
succumbing to scrapie were examined blind by the same
person. Sections from prion-infected mice were semi-
quantitatively assessed for spongiosis, abnormal PrP
accumulation and gliosis, on a scale from 0 to 3, but inter-
mediate scores were given when appropriate (Figure S1).
Spongiform changes were scored as follows: ‘mild’ corre-
sponds to occasional vacuoles, not exceeding two large
vacuoles in a high power field (HPF; 40× objective), and
generally absent orminimalmicrovacuolation in the same
field (Figure S1A), ‘moderate’ or ‘intermediate’ indicates
up to five large vacuoles, often accompanied by a mild
microvacuolation in the same field (Figure S1B) and
‘severe’ indicates more than five vacuoles, often accompa-
nied by a more widespread microvacuolation in the same
field (Figure S1C). Scoring of the deposition of prion
protein, included in addition to the overall density and
intensity, the quality of the stain that is synaptic
(Figure S1D–F) or granular (Figure S1G–I). ‘Synaptic’
deposition was defined by a fine, diffuse and homogenous
immunolabelling with no formation of granules, irregu-
larities or aggregates. A score of ‘mild’ was givenwhen the
immunolabelling showed a fine, homogenous labelling as
shown in Figure S1D. A stronger labelling with a slight
accentuation of neuronal bodies was graded as ‘interme-
diate’ or moderate (Figure S1E) and a robust labelling
reaching saturation of immunostaining was graded as
‘strong’ (Figure S1F). ME7 inoculum was associated with
the formation of coarse granules, and therefore a separate
scoring was applied. A ‘mild’ score was given when occa-
sional granules were seen against a mild synaptic back-
ground, as shown in Figure S1G. A more widespread
presence of granules, which often increased in size, associ-
ated with a stronger synaptic background were scored
as ‘intermediate’, as shown in Figure S1H. Strong
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immunolabelling, with frequent coarse grains, decorating
the majority of neurones in the area, sometimes nearly
confluent were scored as ‘strong’ (Figure S1I). Gliosis,
assessed by immunolabelling of GFAP was scored ‘mild’ if
reactive astrocytes, separated by non-reactive neural
parenchyma, were identified as shown in Figure S1J. A
more dense labelling, with immunoreactivity covering
most or all of the intervening neural parenchyma, was
scored as intermediate (Figure S1K), and the presence of
severely immunoreactive, hypertrophic astrocytes was
scored as ‘severe’ gliosis (Figure S1L). The intensity and
density of microglia staining, carried out on a subset of
sections, matched that of GFAP immunolabelled
astrocytes. Because it did not provide additional informa-
tion, the scoring and correlation with other features was
therefore not carried out.
Identification of brainstem nuclei was carried out by
using corresponding tables of the Paxinos and Franklyn
mouse atlas based on stereotaxic coordinates. The follow-
ing areas were consistently identified and scored for
spongiosis, PrP load and quality and gliosis: vestibular
nuclei (VN), prepositus nucleus (PRN), olive, cerebellum,
latero-dorsal tegmental nuclei, locus coeruleus (LC),
parabrachial nuclei (PBN), gigantocellular reticular
nucleus (GIG), nuclei of the solitary tract (NTS),
ventrolateral reticular medulla (VLRM), pre-Bötzinger
nucleus (PBC) and the nucleus of the sensory portion of
the trigeminal nerve (N CN5). Scoring results of at least
three animals were collated on a spreadsheet (MS Excel
2010; Figure 4). Scores were averaged and cross-
referenced on a separate worksheet in the same file and
visually enhanced by colour codes using the conditional
formatting function. To calculate the intensity variance
between spongiosis, gliosis and prion protein deposition,
standard deviation (SD)was calculated.A small value indi-
cates a parallel development of the three pathologies while
a high value indicates a discrepancy between the different
features. Again, for visual enhancement this was colour
codedusing the conditional formatting function. Similarly,
variability of each of the pathologies (e.g. prion protein
intensity) across different regions was estimated by calcu-
lating the SD across all regions (Figure 1, Figure 4Column
Q). Photographs were taken with a ColorView II digital
camera (http://www.soft-imaging.de Olympus Soft
Imaging Solutions GmbHMünster, Germany)mounted on
a ZEISS Axioplan microscope (Carl ZEISS ltd, Cambridge,
UK) and composedwithAdobePhotoshop (Adobe Systems
Europe Ltd, Maidenhead UK).
Figure 1. Abnormal PrP accumulation in the locus coeruleus of
RML- and ME7-inoculated MloxP and NFH-Cre/MloxP mice. Early
prion pathology in the brainstem of RML and ME7
prion-inoculated MloxP (A–D) and NFH-Cre/MloxP (E,F) mice,
time-culled at an early asymptomatic stage (RML, 6 wpi; ME7,
8 wpi), manifested with deposition of disease-associated prion
protein (red = intermediate, pink = mild, red outline = very mild)
and reactive gliosis [dark yellow = intermediate (A); light
yellow = mild (B,E,F)] in the locus coeruleus (LC), the nucleus of
the solitary tract (NTS) and the pre-Bötzinger complex (PBC). No
spongiform changes were observed at this time point. (A,B,E,F)
Schematic representations adapted from the Paxinos Mouse Atlas,
−5.34 mm (A,E) and −6.84 (B,F) from Bregma. (C,D) Synaptic PrP
deposition in the LC, in RML-inoculated MloxP mice (A), and
granular deposits in ME7-inoculated MloxP mice (D). 4 V, fourth
ventricle; Amb, nucleus ambiguous; LC, locus coeruleus; NTS,
nucleus of the solitary tract; PBC, pre-Bötzinger complex; PBN,
parabrachial nuclei; ROb, raphe obscurus; Sp5, spinal nucleus of
the V nerve; TN, tegmental nuclei; VN, vestibular nuclei. Scale bar
below D = 160 μm.
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Results
Clinical signs suggestive of brainstem
involvement, incubation times and survival
of mice
Brainstem nuclei control essential body functions, such as
motor control, generation of respiratory rhythm and
regulation of blood pressure. In keeping, typical signs that
were observed and monitored in mice with preterminal
and terminal illness were unsteady gate, tremor, ataxia
and abnormal breathing rate. In early and mid-
progression phases, stimulus sensitive cloni and/or startle
reactions could also be evoked. Towards the final disease
stage, animals presented with signs of a spastic paraple-
gia, often accompanied by sustained irregular motor
hyperactivity, interrupted by unresponsive and akinetic
intervals and the development of a slight disturbance that
progressed to a complete loss of the animal’s natural
resting-activity cycle, indicative of impairment of the
reticular formation. RML-inoculated MloxP mice (n = 10)
survived 12.6 weeks (range 12–14 weeks, median 12
weeks), ME7-inoculated MloxPmice (n = 9) survived 16.2
weeks (range 15–17, median 16 weeks), whereas the
‘recombined’ counterparts, NFH-Cre/MloxP mice, sur-
vived for 34.7 weeks after RML inoculation (median 35,
range 30–38 weeks) and 28.9 weeks after ME7 inocula-
tion (median 28, range 29–30 weeks). The survival differ-
ence between RML and ME7 inoculum was statistically
highly significant for both genotypes (RML in NFH-Cre/
MloxP vs. MloxP and ME7 NFH-Cre/MloxP vs. MloxP
P < 0.001), indicating that Cre-mediated PrP recombina-
tion significantly prolonged the incubation time of prion-
infected mice (Figure 2).
Areas of pathology in asymptomatic
prion-infected mice (6–8 wpi)
Detailed analysis of pathological changes in the brainstem
of PrP overexpressing (MloxP) and PrP-depleted (NFH-
Cre/MloxP) mice at early asymptomatic stages (RML,
6 wpi; ME7, 8 wpi) was done on coordinates ranging from
−5.34 mm to −7.64 mm, and included brainstem nuclei
involved in gait and balance (VN, PRN and olive); and
autonomic activity (LC, latero-dorsal TN, PBN, GIG, NTS,
VLRM and PBC). These areas were chosen because motor
activity and autonomic functions (that is respiration) are
usually impaired in terminally ill mice. The cerebellum is
connected with the brainstem through the olivo-
cerebellar pathway, and was analysed to confirm and
characterize in greater detail a previous, unpublished
observation of late cerebellar pathology in longer surviv-
ing terminally ill ME7-infected NFH-Cre/MloxP mice.
InMloxPmice at 6 wpi (RML) or 8 wpi (ME7), PrP accu-
mulation (Figure 3C,D) and gliosis, but no spongiosis were
seen in the LC, the NTS and the PBC, identified by NK1
receptor immunoreactivity. At this stage a subtle prion
deposition pattern difference between ME7-inoculated
(coarse granular) and RML-inoculated mice (fine synap-
tic) was seen (Figure 3C,D). Also in NFH-Cre/MloxP mice,
the LC, NTS and PBC were the only nuclei showing prion
pathology but at a reduced intensity compared with the
non-recombined MloxP mice (Figure 3E,F). Cre-mediated
recombination prolongs survival of prion-infected mice
and slows disease progression in the LC, the nucleus of the
solitary tract and the PBC. To understand the progression
of brainstem pathology, we analysed RML- and ME7-
inoculated MloxP mice at late stages of prion disease
(RML, 12 wpi; ME7, 16 wpi); and NFH-Cre/MloxPmice at
intermediate (RML, 12 wpi; ME7, 16 wpi) or late (RML,
35 wpi; ME7, 28 wpi) stages of prion disease (Figure 4).
Prion pathology in terminally ill,
non-recombined MloxP mice
Clinically ill MloxP mice (RML, 12 wpi; ME7, 16 wpi)
showed an extensive deposition of abnormal PrP in the
Figure 2. Survival of RML- and ME7- inoculated MloxP and
NFH-Cre/MloxP mice. Mice were inoculated with RML or ME7
prions at 1 week of age. MloxP mice (blue line) became terminally
ill at approximately 12 wpi (RML, A) or at approximately 17 wpi
(ME7, B). In contrast to previous experiments, recombined
NFH-Cre/MloxP mice (red) ultimately developed prion disease at
approximately 35 weeks (A) or approximately 29 weeks (B) but
both showed significant delay of their incubation time (P < 0.001).
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Figure 3. Progression of prion pathology in RML- and ME7-inoculated MloxP and NFH-Cre/MloxP mice. Schematic drawings of abnormal
PrP deposition (pink = mild, red = intermediate, dark red = severe) and spongiosis (pale blue = mild, blue = intermediate, dark blue = severe)
of the brainstem nuclei analysed, at four representative levels from coordinates −5.34 mm to −7.64 mm caudal from bregma. The inoculum
is shown on the left margin. Genotype and incubation times on the right margin. (A–D) In terminally ill RML-inoculated MloxP mice
(12 wpi) PrP deposition is seen in different areas of the brainstem, including the locus coeruleus and the olive; prepositus nuclei and
tegmental nuclei; and pre-Bötzinger complex; spongiosis corresponds to PrP deposition in most areas. (E–H) In terminally ill ME7 inoculated
MloxP mice (16 wpi), abnormal PrP deposition was severe in all the nuclei examined, except the gigantocellular nucleus, the ventral medulla
and the cerebellum, where it was intermediate. Spongiosis pattern corresponds to PrP deposition in most areas. (I–L) RML-inoculated
NFH-Cre/MloxP mice show a significantly lower overall accumulation at 12 wpi, and spongiosis was nearly absent everywhere, except for
the locus coeruleus, where it was mild (pale blue). (M–P) In ME7-inoculated NFH-Cre/MloxP mice culled at 16 wpi, abnormal PrP
accumulation was slightly stronger than in RML-inoculated animals and more heterogeneous. Spongiosis was reduced everywhere
compared with ME7-inoculated MloxP mice at end stage of prion disease. Strong PrP deposition and spongiosis was observed in terminally ill
RML-inoculated NFH-Cre/MloxP mice (35 wpi, Q–T), or in terminally ill ME7-inoculated NFH-Cre/MloxP mice (28 wpi) (U–X). 10 N,
nucleus of the X nerve; 12 N, nucleus of the XII nerve; 4 V, forth ventricle; Amb, nucleus ambiguous; LC, locus coeruleus; NTS, nucleus of
the solitary tract; PBC, pre-Bötzinger complex; PBN, parabrachial nuclei; PR N, prepositus nucleus; ROb, raphe obscurus; Sp5, Spinal
nucleus of the V nerve; TN, tegmental nuclei; VLRM, ventro-lateral reticular medulla; VN, vestibular nuclei; VN, vestibular nuclei.
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A B C D E F G H I J K L M N O P Q R
Spongiosis 0.8 1.0 0.7 0.7 1.3 2.0 1.5 0.7 1.0 0.7 0.5 0.2 0.9 0.49
PrP 1.3 1.3 2.3 0.5 2.0 2.5 1.8 1.3 2.3 0.7 1.0 0.7 1.5 0.70
Gliosis 0.5 1.3 0.7 0.5 1.5 2.0 1.0 1.2 1.8 1.3 1.2 0.5 1.1 0.51
AVG 0.9 1.2 1.2 0.6 1.6 2.2 1.4 1.1 1.7 0.9 0.9 0.4 1.2
STDV 0.42 0.19 0.96 0.10 0.35 0.29 0.38 0.35 0.67 0.38 0.35 0.25 0.39
Spongiosis 2.5 2.8 2.0 2.5 2.5 3.0 2.8 1.8 2.7 2.0 1.2 1.5 2.3 0.57
PrP 1.8 1.8 2.0 3.0 2.3 3.0 2.3 1.2 3.0 1.2 1.3 1.0 2.0 0.75
Gliosis 1.8 2.0 2.5 2.2 2.0 2.8 2.3 1.5 2.8 1.8 1.2 1.7 2.1 0.51
AVG 2.2 2.3 2.0 2.8 2.4 3.0 2.6 1.5 2.8 1.6 1.3 1.3 2.1
STDV 0.38 0.54 0.29 0.42 0.25 0.10 0.29 0.33 0.17 0.44 0.10 0.35 0.30
Spongiosis 2.8 2.8 2.2 2.0 3.0 3.0 3.0 2.3 2.8 2.2 1.8 2.3 2.5 0.44
PrP 2.8 2.8 3.0 1.8 2.8 3.0 2.8 2.2 3.0 2.2 3.0 3.0 2.7 0.41
Gliosis 2.3 2.7 2.5 2.0 2.3 2.7 2.0 2.0 2.3 2.0 2.3 2.3 2.3 0.25
AVG 2.8 2.8 2.6 1.9 2.9 3.0 2.9 2.3 2.9 2.2 2.4 2.7 2.6
STDV 0.29 0.10 0.42 0.10 0.35 0.19 0.54 0.17 0.35 0.10 0.63 0.38 0.30
Spongiosis 0.0 0.0 0.2 0.0 0.0 0.7 0.3 0.2 0.0 0.0 0.0 0.0 0.1 0.21
PrP 1.0 1.5 1.2 1.0 1.7 2.5 1.7 1.0 0.8 1.0 0.5 0.8 1.2 0.53
Gliosis 0.5 1.0 1.0 1.0 0.8 0.8 0.8 1.0 1.0 0.8 1.0 0.5 0.9 0.19
AVG 0.5 0.8 0.8 0.7 0.8 1.3 0.9 0.7 0.6 0.6 0.5 0.4 0.7
STDV 0.50 0.76 0.54 0.58 0.83 1.01 0.67 0.48 0.54 0.54 0.50 0.42 0.61
Spongiosis 2.6 2.5 2.5 2.8 2.1 3.0 2.6 1.0 2.8 1.0 1.1 1.4 2.1 0.77
PrP 1.9 2.3 1.5 3.0 2.3 3.0 2.3 1.0 3.0 0.8 1.4 1.1 1.9 0.81
Gliosis 2.0 2.4 2.0 3.0 1.9 3.0 2.0 1.3 2.6 1.5 1.2 1.3 2.0 0.65
AVG 2.3 2.4 2.0 2.9 2.2 3.0 2.4 1.0 2.9 0.9 1.3 1.3 2.0
STDV 0.40 0.13 0.50 0.10 0.19 0.00 0.31 0.14 0.19 0.38 0.13 0.13 0.22
Spongiosis 2.0 2.0 1.5 1.1 1.3 1.4 1.3 1.5 1.7 1.5 1.3 1.5 1.5 0.27
PrP 2.0 2.3 3.0 1.0 2.0 3.0 1.7 1.5 1.3 1.3 1.5 2.1 1.9 0.63
gliosis 2.0 2.3 2.0 0.7 0.8 1.0 0.6 1.5 0.5 1.5 1.3 2.4 1.4 0.68
AVG 2.0 2.1 2.3 1.1 1.7 2.2 1.5 1.5 1.5 1.4 1.4 1.8 1.7
STDV 0.00 0.17 0.76 0.22 0.63 1.06 0.54 0.00 0.60 0.10 0.14 0.46 0.39
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Figure 4. Summary scores from multiple individual experiments. The top two rows (unlabelled) show the anatomical brainstem regions and
their function. Rows A–F show the experimental groups, by inoculum, genotype and incubation time. Above row A, columns A–R provide
reference points for the in text citations of anatomical regions. Each of the rows A–F display the summary scores for spongiosis (blue), PrP
deposition (red) and gliosis (orange), averaged from at least three experimental animals. The colour intensity is directly proportional to the
average scores and was computed with the ‘conditional formatting’ in MS Excel. Below the individual pathology scores, an average of these
values is formed to inform about the overall (average or aggregated) pathology. In addition, the row below this average, the standard
deviation is calculated to indicate low or high variation between the three scores. A low score (light grey) indicates that all three pathologies
develop synchronously in a given region, whereas a high score (dark grey) indicate that the three pathologies develop asynchronously. On
the right, columns Q and R indicate the average and standard deviation across all regions. A low value indicates that all regions show
similar pathology across the entire brainstem (homogenous) and a high value indicates that some areas show a stronger deposition than
others. The legend on the bottom indicates the colours corresponding to scores mild (value 1), moderate (2) and severe (3).
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brainstem. RML-inoculated mice showed more variation
across the different areas (SD 0.63) than those inoculated
with ME7 [(SD = 0.41), Figure 1C,F]. RML inoculation
caused strong deposition in the LC and the olive; followed
by intermediate intensity in the parabrachial, vestibular,
prepositus, tegmental, nuclei, NTS and PBC; and mild
accumulation in the CER and the VLRM (Figure 4A–D
and 4F). Instead, ME7-inoculated mice showed a more
uniform deposition in these areas of the brainstem
(Figures 4E–H and 4C). Both groups showed prominent
spongiform changes and gliosis, which was proportional
to the degree of PrP deposition. However, RML inoculation
resulted in a finer vacuolation pattern (scored as ‘interme-
diate’), whereas in ME7-inoculated brains the vacuoles
were considerably larger (scored as ‘severe’) (Figures 4A–
D,E–H and S1).
Prion pathology in recombined NFH-Cre/MloxP
mice: Differences between RML and ME7 inocula
At the time points when the MloxP mice succumb to
disease (RML, 12 wpi; ME7, 17 wpi) recombined NFH-
Cre/MloxP mice showed very mild prion pathology, which
extended to most grey matter areas in the brainstem
(Figure 4I–L,M–P, Figure 1, RowsA,D). In both RML- and
ME7-inoculated NFH-Cre/MloxP mice, the LC showed the
most intense abnormal PrP deposition (Figure 1, Column
J), followed by the olive, PBN and TN (Figure 1, Columns
G,I,K). RML produced minimal spongiform degeneration
(average score 0.1), and gliosis (average score 0.9)
(Figure 1, Row D, Column Q) while ME7-infected mice
showed mild spongiosis and gliosis in almost all nuclei
(scores 0.9 and 1.1 (Figure 1, Row A, Column Q), with
only the LC and PBN being more affected (Figure 1, Row
A, Column J; Figure 4I–P). In terminally ill NFH-Cre/
MloxP mice (ME7, 28 wpi; RML, 35 wpi; (Figure 1, Rows
C,F), where pathology was most severe, the pattern of
abnormal PrP deposition was very similar in both groups
(Figure 4Q–X). In comparison with non-recombined mice
(Figure 1, Rows C,F), NFH-Cre/MloxP mice (Figure 1,
Rows B,E) showed less intense deposition of abnormal
prion protein, except in the LC, the NTS and the cerebel-
lum, where more abnormal PrP accumulated (Figure 1,
Columns J,M,H). Spongiosis and gliosis were widespread
but with different degrees in different brainstem nuclei.
We also observed abnormal PrP deposition in the tracts of
the cranial nerves (Figure S2C,D) and in the Virchow–
Robin spaces and in the brain parenchyma directly sur-
rounding them (Figure S2E,F). This feature was absent in
terminally ill MloxPmice, raising the possibility that it was
an effect of prolonged production of abnormal prion
protein due to increased survival in (recombined) NFH-
Cre/MloxP mice.
Semi-quantitative cross-regional assessment of
spongiosis, gliosis and PrP deposits reveals
differential patterns of prion pathology
progression in brainstem nuclei
The LC, the NTS and the PBC, identified as first areas of
prion protein accumulation, have an important role in the
control of respiratory and cardiac activity. We hypoth-
esized that their cellular impairment may correlate with
clinical onset and they could indeed be relevant candi-
dates for clinical target areas of prion disease. Following
this initial phase, the kinetics of pathology progression in
these nuclei in ME7-inoculated MloxP and NFH-Cre/
MloxP shows a sharp rise in PrP deposition in the LC, olive
and the NTS initially, followed by other areas ‘catching up’
with prion protein deposition towards the late disease
stage. In RML-inoculated animals, the LC is most affected,
followed by TN and PBN. To generate a comprehensive
map (Figure 1) of the pathologies ‘spongiosis, PrP deposi-
tion and gliosis’, we computed the average scores of all
nuclei in at least three experimental animals. Visualiza-
tion using a ‘heatmap’ algorithm reveals early onsets and
regional differences that are in addition quantified by
forming average values and their standard deviations. We
show here that in early stages spongiosis, gliosis and PrP
develop more synchronously in ME7 (SD of scores 0.39)
than in RML-inoculated animals (SD of scores 0.61)
(Figure 1A,D). Later during disease progression, the
overall SD equalizes between the two inoculum groups,
confirming the visual impression that the spongiosis,
gliosis and PrP deposition ‘saturate’.
The LC (Figure 1, Column J; Figure 5)
At 6 wpi, the deposition in the LC of RML-inoculated
MloxP mice was of intermediate intensity (Figure 5A),
whereas in the PrP-depleted NFH-Cre/MloxP mice, it was
less pronounced (Figure 5D). At 12 wpi, the LC of termi-
nally ill MloxP mice showed strong PrP accumulation
(Figure 1F, Column J; Figure 5D) and mild spongiosis
(Figure 5I) while at the same time the asymptomatic
recombined NFH-Cre/MloxP mice showed intermediate
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levels of PrP accumulation (Figure 1D, Column J;
Figure 5J) and little spongiosis (Figure 5L), due to the
depletion of host PrPC. Terminally ill NFH-Cre/MloxP
showed severe spongiosis, gliosis and prion protein accu-
mulation (Figure 1F; Figure 5M–O).
ME7-infected MloxP mice showed moderate PrP
accumulation at 8 wpi (Figure 5A1), more than in
NFH-Cre/MloxP mice (Figure 5D1), whereas gliosis was
similar (Figure 5B1,E1), and no spongiosis was present
(Figure 5C1,F1). Terminally ill ME7-infected MloxP mice
(16 wpi) showed much heavier PrP accumulation, gliosis
and spongiosis than NFH-Cre-MloxP mice at the corre-
sponding time point (Figure 5G1–L1). Terminally ill NFH-
Cre-MloxP mice (28 wpi) showed strong abnormal PrP
accumulation and spongiosis in the LC, whereas the sur-
rounding areas were almost spared from prion accumula-
tion; gliosis was severe in the LC and surrounding nuclei
(Figure 1C, Column J; Figure 5M1–O1).
The nucleus of the solitary tract (Figure 1,
Column M; Figure 6)
At 6 wpi, the NTS of RML-inoculated MloxP mice was
affected by mild abnormal PrP accumulation and gliosis
(Figure 6A,B), whereas in NFH-Cre/MloxPmice there was
less abnormal PrP accumulation but a similar degree
of gliosis (Figure 6D,E). At 12 wpi, PrP deposition,
spongiosis and gliosis had increased inMloxPmice but not
Figure 5. Progression of prion pathology in the locus coeruleus of RML- and ME7-inoculated MloxP and NFH-Cre/MloxP mice. Sections
were immunostained with ICSM35 antibody for abnormal PrP deposition (left column; RML: A,D,G,J,M; ME7: A1,D1,G1,J1,M1), anti-GFAP
antibody for detection of astrocytosis (middle column; RML: B,E,H,K,N; ME7: B1,E1,H1,K1,N1), and stained with haematoxylin and eosin
(H&E) to assess spongiform changes (right column; RML: C,F,I,L,O; ME7: C1,F1,I1,L1,O1). A–O Pathology in RML inoculated brains: at
6 wpi, there is synaptic PrPSc deposition in MloxP mice (A), or a mild granular deposition in depleted NFH-Cre/MloxP mice (D). No difference
in gliosis (B,E) and no spongiosis (C,F). At 12 wpi (G–L), strong accumulation in the LC of terminally ill MloxP mice (G), but not in
NFH-Cre/MloxP mice was seen. Gliosis was stronger in NFH-Cre/MloxP (K) mice than in control MloxP mice (H). Spongiform changes in
MloxP mice (I) but not in NFH-Cre/MloxP mice (L). M–O terminally ill NFH-Cre/MloxP mice showed accumulation of PrP, gliosis and
spongiosis. A1–O1 Pathology in ME7-inoculated brains: At 8 wpi the abnormal accumulation in the LC of MloxP mice was intermediate
(A1) and less intense in NFH-Cre-MloxP mice (D1) and there was mild gliosis and no spongiosis (B1,C1,E1,F1). At 16 wpi, MloxP mice were
terminally ill and showed strong PrP accumulation, gliosis and spongiosis in and beyond the LC (G1,H1,I1), whereas asymptomatic
NFH-Cre-MloxP were less affected (J1,K1,L1). In terminally ill NFH-Cre-MloxP mice, there was severe LC pathology (M1,N1,O1). Scale
bar = 160 μm in all immunostained sections and 80 μm in the H&E stained sections.
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in depleted NFH-Cre/MloxP mice (Figure 6G–L). In termi-
nally ill NFH-Cre-MloxP mice (35 wpi), reactive gliosis
(Figure 6N) was similar to that in terminally ill MloxP
mice (Figure 6H), and abnormal PrP accumulation was
even stronger than inMloxPmice (compare Figure 6M,G).
ME7-inoculated mice showedminimal granular deposi-
tion of abnormal PrP in the NTS at 8 wpi, a similar degree
of gliosis and no spongiosis (Figure 6A1–F1). By 16 wpi,
MloxP mice showed a substantial aggravation of pathol-
ogy, with severe PrP accumulation, gliosis and spongiosis,
(Figure 6G1–I1), whereas NFH-Cre/MloxP mice showed
reduced pathology (Figure 6J1–L1). At the end
stage (28 wpi), pathology in NFH-Cre/MloxP mice
(Figure 6M1–O1) was similar to 16 wpi MloxP mice.
The PBC (Figure 1, Column O; Figure 7)
At 6 wpi, the PBC of RML-infected MloxP mice showed
mild accumulation and gliosis and no spongiosis
(Figure 7A–C). Almost no pathology was seen in NFH-
Cre/MloxP mice (Figure 7E–G). Upon disease progression,
the effect of recombination became more evident: at
12 wpi, when RML-infected MloxP mice were terminally
ill and RML-infected NFH-Cre/MloxP mice were asympto-
matic, MloxP mice had more prominent pathology than
recombined NFH-Cre/MloxP mice (compare Figure 7I–K
and M–O). Terminally ill NFH-Cre/MloxP mice (35 wpi)
showed the same pathology (Figure 7Q–S) as terminal
(12 wpi) MloxP mice (Figure 1F).
Figure 6. Progression of prion pathology in the nucleus of the solitary tract of RML- and ME7-inoculated MloxP and NFH-Cre/MloxP mice.
Sections were immunostained with ICSM35 antibody for abnormal PrP deposition (left columns) anti-GFAP antibody for detection of
astrocytosis (middle columns) and stained with haematoxylin and eosin (H&E) to assess spongiform changes (right columns). (A–O) RML
inoculated MloxP mice (6 wpi) showed mild abnormal PrP accumulation, gliosis and no spongiosis (A–C). At the same time, NFH-Cre-MloxP
mice showed a similarly mild pathology (D–F). At 12 wpi, terminally ill MloxP mice (G–I) showed more PrP accumulation, strong gliosis and
minimal spongiosis. At the same time NFH-Cre/MloxP mice showed similar PrP accumulation but less gliosis and no spongiosis (J–L).
Terminally ill NFH-Cre-MloxP mice showed stronger PrP accumulation, gliosis and spongiosis, similar to terminally ill MloxP mice (G–I).
A1–O1 ME7-inoculated mice showed minimal PrP deposition, no spongiosis and moderate gliosis at 8 wpi (A1–F1) and a rapid progression
to a more severe pathology at 16 wpi, when MloxP mice are terminal (G1–L1). At end stage (M1–O1), NFH-Cre/MloxP mice showed severe
pathology with abundant PrP, intense gliosis and moderate spongiosis. Scale bar = 160 μm.
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In ME7-infected MloxP mice, there was mild pathology,
similar to NFH-Cre/MloxP mice (Figure 7A1–C1 and
E1–G1). At 16 wpi, terminally ill MloxP mice showed
strong prion protein deposition, gliosis and spongiosis
(Figure 7I1–K1; Figure 1C, average PrP score 2.7),
whereas NFH-Cre/MloxP mice showed only mild PrP
deposition (Figure 7M1–O1; Figure 1A, average PrP score
1.5). Terminally ill NFH-Cre/MloxPmice (Figure 7Q1–S1)
showed the effect of PrP depletion, with levels of reactive
gliosis and spongiosis comparable with terminally ill
MloxP mice but reduced PrP accumulation (Figure 1A,
average PrP score 2.0).
In summary, in both RML- and ME7-inoculated MloxP
andNFH-Cre/MloxPmice, the appearance of spongiosis in
the LC, NTS and PBC, which were the first areas of pathol-
ogy, correlate with the appearance of clinical signs. As
neurodegeneration in these nuclei correspond to manifes-
tation of clinical phenotype and because of their funda-
mental role in control of autonomic function, we
speculate that these nuclei may represent clinical target
areas of prion disease.
Analysis of recombination in the LC, the nucleus
of the solitary tract and the PBC
PrP-depleted NFH-Cre/MloxP mice survive significantly
longer than non-recombined MloxP mice but accumulate
prion protein and infectivity (Figures 1,2,4–6). This is
reflected in the heavy accumulation of prion protein in the
brainstem of NFH-Cre/MloxP mice. At their asympto-
matic stages, LC, NTS and PBCwere the first areas to accu-
mulate prion protein and to develop spongiform changes.
Sustained survival of NFH-Cre/MloxP mice is due to PrP
deletion in specific neuronal populations [26]. We there-
Figure 7. Progression of prion pathology in the pre-Bötzinger complex of RML-and ME7-inoculated MloxP and NFH-Cre/MloxP mice.
Sections were immunostained with ICSM35 antibody for abnormal PrP deposition (left column) anti-GFAP antibody for detection of
astrocytosis (second column) and stained with haematoxylin and eosin (H&E) to assess spongiform changes (third column) and NK1
Receptor (right column). A–T RML-inoculated MloxP mice (6 wpi) showed mild to moderate abnormal PrP accumulation, gliosis and no
spongiosis (A–C). At the same time, NFH-Cre/MloxP mice showed a similarly mild pathology (E–G). At 12 wpi, terminally ill MloxP mice
(I–K) showed more PrP accumulation, strong gliosis and minimal spongiosis. At the same time NFH-Cre/MloxP mice showed similar PrP
accumulation but less gliosis and no spongiosis (M–O). Terminally ill NFH-Cre-MloxP mice showed still a moderate PrP accumulation, gliosis
and spongiosis, similar to terminally ill MloxP mice (I–K). There is some inconsistency of progression, as the gliosis in (E) is stronger than
that in (K), indicating a possible variance in transgene recombination efficacy. The right column demonstrates the NK1R immunolabelling of
the pre-Bötzinger complex. A1–T1 ME7-inoculated MloxP and NFH-Cre/MloxP mice show minimal PrP deposition, no spongiosis and
moderate gliosis at 8 wpi (A1–C1, E1–G1). At 16 wpi more severe pathology, with abundant PrP deposition, severe gliosis and spongiosis
was observed in terminally sick MloxP mice (I1–K1) but not asymptomatic NFH-Cre/MloxP mice (M1–O1). At end stage (Q1–S1),
NFH-Cre/MloxP mice showed severe pathology with abundant PrP, intense gliosis and moderate spongiosis. Right column, NK1R
immunolabelling to verify the pre-Bötzinger complex. Scale bar = 160 μm.
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fore analysed the Cre-mediated recombination in the
brainstem, by crossing NFH-Cre mice with ROSA26lox
reporter mice, which express β-galactosidase upon Cre-
mediated removal of a stop codon between the ROSA26
promoter and the lacZ gene [30]. Brainstem sections from
NFH-Cre/ROSA26 mice encompassing the LC, the NTS
and the PBC were stained with an anti-β-galactosidase
antibody. In this reporter strain, β-galactosidase diffusely
accumulates in the cytoplasm and typically also forms
small intracellular cytoplasmic inclusions that can be
visualized by immunostaining. In the LC, we found
that approximately half of the cells accumulate β-
galactosidase, indicating partial recombination. In the
NTS and PBC, recombination was less frequent but still
evident (Figure 8A1–B2). These data suggest that Cre-
mediated recombination in the target areas was incom-
plete, which could explain why the LC, NTS and PBC
ultimately developed prion pathology.
Discussion
We studied the disease progression in the brainstem of
prion-infected mice in PrP overexpressing MloxP and PrP-
depleted NFH-Cre/MloxP mice to evaluate the clinical
target areas of prion disease. Signs of functional impair-
ment of the brainstem in humans are vertigo, nystagmus
(inferior vestibular nucleus and inferior cerebellar pedun-
cle), nausea and vomiting (area postrema), dysarthria and
dysphonia (nucleus ambiguus), singultus (respiratory
centre of the reticular formation), ipsilateral flaccid
hypoglossal nerve palsy, hemiplegia (contralateral to
lesion) with Babinski’s sign (contralateral to lesion) and
posterior column hypaesthesia (that is hypaesthesia to
touch and pressure, with impaired position sense). Syn-
drome of the caudal base of the pons present with ipsilat-
eral abducens palsy and nuclear facial palsy, analgesia,
thermanaesthesia, and impairment of touch, position and
vibration sense. Although only selected clinical signs can
be monitored in mice with progressive prion disease, a
number of key brainstem signs could be mapped to the
nuclei that showed early and most progressive prion
pathology, including early (clumsiness or lack of coordi-
nation, insomnia) and late symptoms in sporadic and iat-
rogenic CJD (visual deterioration and eventual blindness,
myoclonus and paralysis, slurred speech, difficulty
swallowing and incontinence). Here, prion pathology
first occurs in the thalamus and brainstem in PrP
overexpressing RML-inoculated [27] and ME7-inoculated
mice (Figure S3) and subsequently spreads to other brain
areas. The first brainstem target areas of prion pathology
are the LC, NTS and PBC. Due to Cre-mediated recombi-
nation and removal of neuronal PrPC, prion-infectedNFH-
Cre/MloxP mice survive two- to threefold longer than
MloxP mice, depending on the prion strain (RML or ME7).
Although still significantly prolonged, the survival in
RML-inoculated NFH-Cre/MloxP mice was shorter than
seen previously, thought to be caused by a shift of recom-
bination efficiency and timing in this line over multiple
generations [26]. However, ultimately, terminal ill mice all
show severe spongiosis in the LC, NTS and PBC.The rate of
progression of pathology in these nuclei is slower in NFH-
Cre/MloxPmice because of partial neuronal PrPC removal
through Cre-mediated PrP excision. As determination of
PrPC via biochemical or immunohistochemical means
would be inaccurate due to the variability between adja-
cent anatomical areas or even between individual cells in
an area, we used a high-resolution histological assessment
Figure 8. Cre-mediated recombination in the locus coeruleus (LC),
the nucleus of the solitary tract (NTS) and the pre-Bötzinger
complex (PBC) of NFH-Cre/ROSA26 mice. A,B schematic
representations adapted from the Paxinos Mouse Atlas, coordinates
−5.34 mm (A) and −6.84 mm (B) from Bregma. A1,B1,B2
β-galactosidase immunoreactivity in the LC (A1), the NTS (B1) and
the PBC (B2) of NFH-Cre/ROSA26 mice. Immunostaining for
β-galactosidase is characterized by a diffuse accumulation in the
cytoplasm as well as few small intracellular cytoplasmic inclusions.
In the LC, ca. half of the cells express β-galactosidase, indicating
partial recombination (A1). In the nucleus of the solitary tract (B1)
and in the pre-Bötzinger complex (B2), recombination was less
widespread. Scale bar = 80 μm.
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of recombination using NFH-Cre mice crossed with the
ROSA26LoxP reporter mouse strain [30] to assess efficacy of
recombination in the postulated target areas. Indeed, by
determining the recombination using the surrogate
marker β-galactosidase in NFH-Cre/ROSA26LoxP mice, we
show that Cre-mediated recombination is incomplete in
these areas (Figure 8), and hence NFH-Cre/MloxP mice
are not completely spared by prion pathology.
Key clinical target areas of prion disease have been
definedascriticalvulnerableareas, inwhichprion-induced
neurodegeneration must occur for clinical disease to
develop [23]. A strain associated tropism have been sug-
gested and may explain the difference in PrP colonization
dynamics and anatomical involvement in RML- and ME7-
inoculated mice [33,34]. The vital role of the LC, NTS and
PBC in controlling autonomic functions suggests that
neurodegenerationof theseareasare likely to contribute to
thedevelopment of clinical symptoms.TheLC is implicated
in autonomic activities, such as control of respiration [35–
37] and cardiovascular function [38], in keeping with
symptoms of terminally ill CJD patients. Specifically, LC
neurones participate in the central respiratory network
[39] and exhibit chemosensitive signalling behaviour
[40,41]. Pathological involvement of the LC is also known
inRett syndrome [42], andmultiple systematrophy (MSA)
[43].
The nucleus of the solitary tract is a relay nucleus for
integration and modulation of autonomic activity. Many
NTS neurones have respiratory-related activity and
central respiratory modulation [44–46], detect changes
in pCO2 in vivo, respond directly to acid in vitro [47] and
respond to arterial baroreceptors [48–50]. It has been
suggested that NTS neurones may have a role in
impaired ventilator response MSA when activated by
hypoxia [51]. The NTS is one of the first areas of prion
accumulation in a model of oral infection, thought to
ascend via the dorsal motor nucleus of the vagal nerve
[52]. Our findings suggest that the NTS is also a particu-
larly vulnerable area upon intracranial inoculation.
Autonomic disturbances are key clinical signs in termi-
nal CJD.
PBC neurones are characterized by neurokinin 1 recep-
tor immunoreactivity [53]. We took advantage of this
property to confirm the identity of the group of cells
showing early abnormal PrP accumulation in the ventral
medulla. The PBC is the centre of respiratory rhythm gen-
eration [54–58], and ex vivo studies of abolishing PBC
function stops rhythm generation [58]. Impairment of
PBC function plays a role in Rett syndrome [59], sudden
infant death syndrome [60] and MSA [51]. The role of
these nuclei (LC, NTS and PBC) in controlling respiratory
and cardiac activity and their early involvement in prion
pathology suggest they could represent clinical target
areas of prion disease. In both RML-and ME7-inoculated
NFH-Cre/MloxP mice (that is mice with reduced PrP
expression), LC and NTS showed severe PrP accumula-
tion, spongiosis and gliosis. In our model, Cre-mediated
recombination in the clinical target areas (LC, NTS and
PBC) is incomplete, and this could explain that these
nuclei ultimately succumb to prion pathology.
Although previous work investigated the kinetics of
prion accumulation in the brain of hamsters and trans-
genic mice expressing hamster PrP [61], to our knowl-
edge, this is the first detailed histopathological analysis of
prion disease in the brainstem of experimental mice.
However, prion disease-related pathology in nuclei
involved in control of autonomic functions has been
reported for different experimental and naturally occur-
ring prion diseases. In hamsters, orally infectedwith 263K
prions, the dorsal motor nucleus of the vagus nerve fol-
lowed by the NTS were found to be the first target areas of
prion pathology [52]. Involvement of the vagus nerve and
the NTS has been reported also in natural and experimen-
tal cases of BSE in cattle, confirming the vagal parasym-
pathetic fibre as a route for spreading of prion from
periphery to the CNS [62,63]. Bradycardia, as an effect of
increased vagal tone [64,65] and heart rate variability
[66], has been reported in cattle orally challenged with
BSE, but ECG variability does not correlate with evidences
of heart disease [67]. In a murine model of BSE, early
vulnerability of the central serotonergic system was sup-
ported by behavioural and anatomical-pathological obser-
vation [68]. Moreover, in BSE-infected cattle, spongiform
lesions and abnormal PrP accumulation was reported in
the auditory brainstem nuclei and associated with clinical
dysfunction of the auditory system, providing a rationale
to use auditory dysfunction as a test for antemortem BSE
diagnosis [69].
In summary, we followed the progression of prion
pathology in the motor and autonomic centres of the
brainstem in mice intracerebrally inoculated with prions
and found that LC, NTS and PBC are areas of early prion
deposition. As their degeneration corresponds to the
manifestation of the clinical phenotype and because of
their fundamental role in control of autonomic function,
we hypothesize that these nuclei play a role in target areas
14 I. Mirabile et al.
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of prion disease, in particular in the view of the significant
overlap to neurological signs in human sporadic CJD.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. Scoring system used to evaluate prion pathol-
ogy in the brainstem of prion inoculated animals.
Spongiosis was scored considering the ratio between
healthy tissue and vacuoles in a given nucleus, observed
by H&E staining, as mild = 1 (A), intermediate = 2 (B) or
severe = 3 (C). Abnormal PrP accumulation was scored
according to synaptic density of abnormal PrP deposits (D,
E, F) or granularity (G, H, I), as observed by ICSM 35
antibody staining. Synaptic densitywas scored asmild (D),
intermediate = 2 (E) or severe = 3 (F); granularity was
scored as mild = 1 (G), intermediate = 2 (H) or severe = 3
(I). Gliosis was scored taking into account proportion of
reactive cells and the intensity of GFAP staining, as
mild = 1 (J), intermediate = 2 (K) or severe = 3 (L). Scale
bar = 160 μm.
Figure S2. Abnormal PrP accumulation in the cranial
nerves and in the Virchow-Robin space of RML and ME7
inoculated NFH-Cre/MloxP mice. In RML and ME7 inocu-
lated NFH-Cre/MloxP mice PrP deposition was also found
in areas spared in RML inoculated MloxP mice, like the
tracts of the cranial nerves (A, B, C, D) and the Virchow-
Robin spaces (A, B, E, F), suggesting that the prolonged
survival allows the spread of prions in areas not primarily
targeted by the infection, and highlighted the similarity in
the lesion profiles of RML and ME7 inoculated NFH-Cre/
MloxP mice. Scale bar = 2 mm (A, B); 60 μm (C–F).
Figure S3. Progression of abnormal PrP deposition in the
brains of ME7 inoculated MloxP and NFH-Cre/MloxP
mice. (A) It has been previously shown that in RML inocu-
latedMloxPmice abnormal PrP deposition accumulates at
6 wpi in the brainstem. By 8 wpi it spreads to the
hippocampus and the thalamus, than to the cortex
(10 wpi) and by terminal stage it is diffuse in the whole
brain (adapted from [30]). (B) ME7 inoculated MloxP and
NFH-Cre/MloxP mice were time culled at different times
post inoculation (wpi). 3 brains per group were analysed.
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Abnormal PrP deposition in ME7 inoculated MloxP mice
was first found at 8 wpi, in the thalamus and the
brainstem; by 10 wpi it spread to the cortex and
hippocampus and became more intense in the thalamus
and brainstem; by 16 wpi it involved the cerebellum. At
the end stage of the disease, (approximately 17 wpi)
abnormal PrP accumulation was widespread in all brain
areas, with maximal intensity in the thalamus and
brainstem. In NFH-Cre/MloxP mice, the pattern of PrP
deposition at 8 wpi was similar to that observed in MloxP
mice, but at 10 wpi the abnormal PrP deposition was
milder. At 12 wpi, intense staining was localized in the
thalamus and brainstem; at approximately 16 wpi deposi-
tion spread to cerebellum, striatum, and cortex, but the
thalamic nuclei, which were the first area of accumula-
tion, and the hippocampus were spared. At 20 wpi the
areas of maximal accumulation were: cortex, caudo-
putamen, frontal thalamus, posterior hippocampus,
brainstem, and cerebellum. At the end stage of disease
frontal hippocampus and ventral thalamic nuclei showed
milder abnormal accumulation compared to end stage
MloxP mice. Brains were stained with antibody ICSM35,
scale bar = 1.7 mm for brains labelled with *; 2.2 mm for
all the other brains.
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